Viral Hepatitis

You have full text access to this OnlineOpen article

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients†‡

  1. Sarah L. George1,3,5,§,*,
  2. Bruce R. Bacon1,2,
  3. Elizabeth M. Brunt1,4,
  4. Kusal L. Mihindukulasuriya1,2,
  5. Joyce Hoffmann1,2,
  6. Adrian M. Di Bisceglie1,2

Article first published online: 13 NOV 2008

DOI: 10.1002/hep.22694

Issue

Hepatology

Hepatology

Volume 49, Issue 3, pages 729–738, March 2009

Additional Information

How to Cite

George, S. L., Bacon, B. R., Brunt, E. M., Mihindukulasuriya, K. L., Hoffmann, J. and Di Bisceglie, A. M. (2009), Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology, 49: 729–738. doi: 10.1002/hep.22694

Author Information

  1. 1

    Saint Louis University Liver Center and the Division of Gastroenterology, Department of Internal Medicine, Saint Louis University, St. Louis, MO

  2. 2

    Division of Hepatology, Department of Internal Medicine, Saint Louis University, St. Louis, MO

  3. 3

    Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University, St. Louis, MO

  4. 4

    Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO

  5. 5

    Research Service, St. Louis Veterans Affairs Medical Center, St. Louis, MO

  1. §

    fax: 314-771-3816

*Division of Infectious Diseases, Department of Internal Medicine, Saint Louis University, Doisy Research Building, 8th Floor, 1100 S. Grand Boulevard, St. Louis, MO, 63104

  1. †

    This work was presented in part at the 13th International Conference on Hepatitis C and Related Flaviviviruses, August 2006, Cairns, Australia, and at the annual meeting of the American Association for the Study of Liver Diseases, October 2006, Boston, MA.

  2. ‡

    Potential conflict of interest: Dr. Bacon is a consultant for, is on the speakers' bureau of, and received grants from Schering Plough. He received grants from Roche and Bristol-Myers Squibb. He is on the speakers' bureau of Gilead Sciences and Three Rivers. He received grants from and is a consultant for Coley Pharmaceuticals, ISIS, and Valeant. He advises and received grants from GlaxoSmithKline. Dr. Brunt received grants from Roche. Dr. Di Bisceglie is a consultant for Schering-Plough. He is also a consultant for, advises, and received grants from Roche.

  3. §

    fax: 314-771-3816

Publication History

  1. Issue published online: 24 FEB 2009
  2. Article first published online: 13 NOV 2008
  3. Accepted manuscript online: 13 NOV 2008 12:00AM EST
  4. Manuscript Accepted: 8 OCT 2008
  5. Manuscript Received: 14 AUG 2008

Funded by

  • Merit Review grant from the Department of Veteran's Affairs
  • National Institutes of Health Grant. Grant Number: DK41816
  • Saint Louis University Liver Center Grant
  • Schering Plough

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (640K)

References

  • 1
    Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–1432.
  • 2
    McHutchison JG, Gorelick RJ, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng J Med 1998; 339: 1485–1492.
  • 3
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Int Med 1997; 127: 875–881.
  • 4
    Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle J. 10-year follow-up after interferon therapy for chronic hepatitis C. HEPATOLOGY 1998; 28: 1121–1127.
    Direct Link:
  • 5
    Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30: 783–787.
  • 6
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann P, Zeusem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Int Med 2007; 147: 677–684.
  • 7
    Poynard T, McHutchinson JG, Manns M, Trepo C, Lindsay KL, Goodman Z, et al. Impact of pegylated interferon alpha 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.
  • 8
    Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525–1528.
  • 9
    Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. HEPATOLOGY 1993; 18: 1300–1305.
    Direct Link:
  • 10
    Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-α therapy for chronic hepatitis C virus infection. J Hepatol 2007; 27: 49–55.
  • 11
    Camma C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P, et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531–537.
  • 12
    Pradat P, Tillmann HL, Sauleda S, Braconnier J-H, Saracco G, Thursz M, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat 2007; 14: 556–563.
    Direct Link:
  • 13
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 2000; 132: 517–524.
  • 14
    Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504–1508.
  • 15
    Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. HEPATOLOGY 2000; 31: 241–246.
    Direct Link:
  • 16
    Fanson B, Osmack P, Di Bisceglie AM. A comparison between the phenol-chloroform method of RNA extraction and the QIAamp viral RNA kit in the extraction of hepatitis C and GB virus-C/hepatitis G viral RNA from serum. J Virol Methods 2000; 89: 23–27.
  • 17
    Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, et al. Performance Evaluation of the VERSANT HCV RNA qualitative assay by using transcription-mediated amplification. J Clin Micro 2003; 41: 310–317.
  • 18
    Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126–133.
    Direct Link:
  • 19
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005; 40: 688–696.
  • 20
    Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. HEPATOLOGY 2003; 38: 493–502.
    Direct Link:
  • 21
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148–156.
View Full Article with Supporting Information (HTML) Get PDF (640K)